SkilaMederi Announces Kilian Weiss as Chief Executive Officer and Dr. Richard Nichol as Chairman of the Board
Morris Plains, NJ, April 07, 2012 --(PR.com)-- SkilaMederi, a leading provider of key opinion leader (KOL) and launch management solutions using software and social network analytics serving the life science industry, is pleased to announce the appointment of Kilian Weiss as Chief Executive Officer (CEO) and Dr. Richard Nichol as Chairman of the Board. Drew McCartney, former CEO of SkilaMederi, will continue to remain on the Board and will focus on his role as an operating partner at BelHealth Investment Partners.
Harold S. Blue, Managing Partner of BelHealth Investment Partners L.P. (BelHealth), and former Chairman of the Board of SkilaMederi, said “Kilian is one of the pioneers in the use of social analytics for the pharmaceutical industry and has a deep understanding of what the market needs. He is also the single largest shareholder of SkilaMederi. I am confident that with this appointment, the company has the expanded leadership to build on its existing strengths and is well-positioned for rapid growth. In appointing Dr. Nichol as Chairman, the Board has been very impressed with Dr. Nichol’s insight and vision for the company and believes, as Chairman, Dr. Nichol can effectively guide Kilian and the rest of the organization to establish SkilaMederi as the de facto standard in product launch management and social analytics solutions.”
Commenting on his appointment as CEO of SkilaMederi, Kilian Weiss said, “I am excited to be assuming the role of CEO. SkilaMederi benefits from significant relationships with several of the largest life sciences companies and I look forward to expanding those relationships. This is an exciting period and we have a stellar team to capitalize on our unique positioning in the marketplace.”
“Having spent a significant time on strategy and positioning with Kilian and the rest of the SkilaMederi team over the past four months, I am convinced of great opportunities ahead and I look forward to utilizing my experience in the life sciences industry to guide the team as Chairman,” said Dr. Richard Nichol.
Drew McCartney said “as the CEO of Skila and as an operating committee member of BelHealth, over the past seven months we have accomplished our interim goal of rebuilding our infrastructure for growth and consummating the merger with Mederi, which is a perfect fit both strategically and tactically. With Kilian at the helm, we look to SkilaMederi as a breakout player in the segment. As an active board member, I am thrilled with the opportunity to mentor Kilian. This move also allows me to direct my focus toward growing and managing healthcare companies as a member of BelHealth’s operating committee.”
Simon Mason, President of SkilaMederi, said “Social media intelligence is transforming the way business is conducted in Big Pharma. Having spent 15 years at Skila and more than 20 years in the pharmaceutical industry I have never been more positive or exhilarated about what we can now provide to our customers. I am looking forward to working closely with Kilian during this exciting phase.”
To learn more about the two companies please visit www.skila.com and www.mederi.net.
Harold S. Blue, Managing Partner of BelHealth Investment Partners L.P. (BelHealth), and former Chairman of the Board of SkilaMederi, said “Kilian is one of the pioneers in the use of social analytics for the pharmaceutical industry and has a deep understanding of what the market needs. He is also the single largest shareholder of SkilaMederi. I am confident that with this appointment, the company has the expanded leadership to build on its existing strengths and is well-positioned for rapid growth. In appointing Dr. Nichol as Chairman, the Board has been very impressed with Dr. Nichol’s insight and vision for the company and believes, as Chairman, Dr. Nichol can effectively guide Kilian and the rest of the organization to establish SkilaMederi as the de facto standard in product launch management and social analytics solutions.”
Commenting on his appointment as CEO of SkilaMederi, Kilian Weiss said, “I am excited to be assuming the role of CEO. SkilaMederi benefits from significant relationships with several of the largest life sciences companies and I look forward to expanding those relationships. This is an exciting period and we have a stellar team to capitalize on our unique positioning in the marketplace.”
“Having spent a significant time on strategy and positioning with Kilian and the rest of the SkilaMederi team over the past four months, I am convinced of great opportunities ahead and I look forward to utilizing my experience in the life sciences industry to guide the team as Chairman,” said Dr. Richard Nichol.
Drew McCartney said “as the CEO of Skila and as an operating committee member of BelHealth, over the past seven months we have accomplished our interim goal of rebuilding our infrastructure for growth and consummating the merger with Mederi, which is a perfect fit both strategically and tactically. With Kilian at the helm, we look to SkilaMederi as a breakout player in the segment. As an active board member, I am thrilled with the opportunity to mentor Kilian. This move also allows me to direct my focus toward growing and managing healthcare companies as a member of BelHealth’s operating committee.”
Simon Mason, President of SkilaMederi, said “Social media intelligence is transforming the way business is conducted in Big Pharma. Having spent 15 years at Skila and more than 20 years in the pharmaceutical industry I have never been more positive or exhilarated about what we can now provide to our customers. I am looking forward to working closely with Kilian during this exciting phase.”
To learn more about the two companies please visit www.skila.com and www.mederi.net.
Contact
SkilaMederi
Elaine M. Nowak
(973) 889-1300
www.skila.com
Elaine M. Nowak
(973) 889-1300
www.skila.com
Contact
Categories